The seventh Longevity Investors Conference in Gstaad centered on evidentiary standards rather than ambition, with researchers urging investors to demand control groups, replication and clinically meaningful endpoints before accepting claims of biological age reversal. Organizers noted that while first-in-human work in cellular reprogramming and aging-targeted interventions is underway, no human life extension has yet been demonstrated. The discussion marks a shift in how capital evaluates the translation of geroscience into measurable human benefit.
Key Points
- No demonstrated human life extension despite accelerating first-in-human trials
- Horvath's criteria for age-reversal claims: control group, context, clock
- Barzilai: aging precedes disease, making aging biology a unified target
Longevity Analysis
The discipline advocated here — control groups, replication, clinically relevant endpoints — is the same discipline that separates useful personal intervention from expensive noise. Claims of biological age reversal rest on clocks and composite markers whose signals are easily misread, and interpreting them correctly requires knowing what the measurement actually tracks and under what conditions. Targeting the mechanisms of aging rather than individual diseases implies that interventions supporting repair capacity, metabolic output and immune regulation act across multiple systems at once, which raises both the potential benefit and the standard of proof required.
Original published by Longevity.Technology, by Eleanor Garth.